Clinical profile of an atypical antipsychotic: Risperidone

Schizophrenia Bulletin

Volumn 28, Issue 1, 2002, Pages 43-61

  Davis, John M ^a   Chen, Nancy ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Atypical antipsychotics; Extrapyramidal side effects; Risperidone; Schizophrenia treatment

Indexed keywords

HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SERTINDOLE; ZIPRASIDONE;

ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; EXTRAPYRAMIDAL SYMPTOM; HOSPITALIZATION; HUMAN; META ANALYSIS; NEGATIVE SYNDROME; PARANOIA; PRIORITY JOURNAL; SCHIZOPHRENIA; SIDE EFFECT; WEIGHT GAIN; DRUG EFFECT; DYSKINESIA; NEUROLOGIC EXAMINATION; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; DYSKINESIA, DRUG-INDUCED; HUMANS; NEUROLOGIC EXAMINATION; PSYCHIATRIC STATUS RATING SCALES; RANDOMIZED CONTROLLED TRIALS; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 0035988523     PISSN: 05867614     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.schbul.a006925     Document Type: Article

References (55)

1. Practice guideline for the treatment of patients with schizophrenia
2. Multiple fixed doses of "seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo
3. Olanzapine versus placebo and haloperidol: Acute phase results of the North American double-blind olanzapine trial
4. Antipsychotic and anxiolytic properties of risperidone, haloperidol, and levomepromazine in schizophrenic patients
5. Comprehensive Metaanalysis: A Computer Program for Research
6. Risperidone: Clinical safety and efficacy in schizophrenia
7. Longitudinal comparative study of risperidone and conventional neuroleptics for treating patients with schizophrenia
8. Differential efficacy of risperidone versus haloperidol in psychopathological subtypes of subchronic schizophrenia
9. Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses
10. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients
11. Review of clinical and laboratory experiences with molindone hydrochloride
12. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: A multicenter double-blind comparative trial
13. Risperidone vs. Haloperidol for prevention of relapse in schizophrenia and schizoaffective disorders: A long-term double-blind comparison
14. The effects of olanzapine on the 5 dimensions of schizophrenia derived by factor analysis: Combined results of the North American and international trials
15. Comparisons of the effects of the newer atypical antipsychotics in the treatment of schizophrenia: A meta-analysis
16. Antipsychotics: Past and future
17. Risperidone in the treatment of first episode psychotic patients: A double-blind multicenter study
18. Atypical antipsychotics in the treatment of schizophrenia: Systematic overview and meta-regression analysis
19. Effects of a phenothiazine and/or group psychotherapy with schizophrenia
20. Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations
21. Risperidone versus zuclopenthixol in the treatment of acute schizophrenic episodes: A double-blind parallel-group trial
22. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia
23. Pyramidical model of schizophrenia
24. Risperidone versus typical antipsychotic medication for schizophrenia
25. The schedule for the deficit syndrome: An instrument for research in schizophrenia
26. Jeste double-blind comparison of Risperidone vs Haloperidol in older patients with schizophrenia or schizoaffective disorder
27. Factorial structure of the Positive and Negative Syndrome Scale (PANSS): A forced five-dimensional factor analysis
28. Translating research into practice: The Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations
29. Efficacy and extrapyramidal side effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: A meta-analysis of randomized controlled trials
30. Window of opportunity: Intervening in schizophrenia when recovery is possible
31. A new five factor model of schizophrenia
32. Principal component analysis of the Swedish version of the Positive and Negative Syndrome Scale for schizophrenia
33. Risperidone vs Conventional Antipsychotics in usual care: A prospective randomized effectiveness trial of outcomes for patients with schizophrenia and schizoaffective disorder
34. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: Combined results of the North American Trial
35. Risperidone in the treatment of schizophrenia
36. Risperidone: How good is the evidence for efficacy?
37. Olanzapine on trial
38. The expert consensus guideline series: Treatment of schizophrenia
39. The Texas Medication Algorithms Project (TMAP) schizophrenia algorithms
40. Risperidone versus haloperidol in the treatment of chronic schizophrenic patients: A parallel group double-blind comparative trial
41. Phenothiazine treatment in acute schizophrenia
42. Consultant for the pharmacotherapy of schizophrenia
43. The brief psychiatric rating scale
44. A new algorithm for treating schizophrenia
45. Design and analysis of randomized clinical trials requiring prolonged observation of each patient: II. Analysis and examples
46. Risperidone in the treatment of patients with chronic schizophrenia: A multi-national, multi-centre, double-blind, parallel-group study versus haloperidol
47. Atypical antipsychotics: Are some more atypical than others?
48. Loxapine versus chlorpromazine in paranoid schizophrenia: A double-blind study
49. Risperidone in treatment-refractory schizophrenia
50. Efficacy and safety of sertindole in a trial of schizophrenic patients
51. Risperidone versus haloperidol in the treatment of acute exacerbations of chronic inpatients with schizophrenia: A randomized double-blind study
52. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia